Gilead Sciences (GILD) Convertible Debt (2009 - 2010)
Gilead Sciences' (GILD) quarterly Convertible Debt came in at $2.8 billion in Q4 2010, up 145.67% YoY from $1.2 billion in Q4 2009, and up 0.7% on a QoQ basis from $2.8 billion in Q3 2010.
Gilead Sciences (GILD) Convertible Debt (2009 - 2010) Analysis & Trends
Gilead Sciences (GILD) has 2 years of Convertible Debt data on file, last reported at $2.8 billion in Q4 2010.
- Quarterly Convertible Debt rose 145.67% year-over-year to $2.8 billion in Q4 2010, while the trailing twelve-month figure through Dec 2010 was $2.8 billion (up 145.67% YoY) and the FY2010 annual result came in at $2.8 billion, up 145.67% from the prior year.
- Convertible Debt improved to $2.8 billion in Q4 2010, from $2.8 billion in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $2.8 billion in Q4 2010 to a low of $1.1 billion in Q2 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.33 Bn | 630.58 Bn | 17.26 Bn |
| 2 | AbbVie | 469.67 Bn | 463.10 Bn | 12.70 Bn |
| 3 | Merck | 374.13 Bn | 366.99 Bn | 12.21 Bn |
| 4 | Novartis Ag | 302.76 Bn | 295.07 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.15 Bn | 252.25 Bn | 12.86 Bn |
| 6 | Amgen | 236.76 Bn | 222.77 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 182.54 Bn | 179.36 Bn | 6.22 Bn |
| 8 | Pfizer | 159.57 Bn | 147.87 Bn | 10.94 Bn |
| 9 | Gsk | 105.99 Bn | 101.83 Bn | 8.24 Bn |
| 10 | Sanofi | 55.15 Bn | 47.77 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 2.84 Bn |
| Sep 30, 2010 | 2.82 Bn |
| Mar 31, 2010 | 1.17 Bn |
| Dec 31, 2009 | 1.16 Bn |
| Sep 30, 2009 | 1.14 Bn |
| Jun 30, 2009 | 1.13 Bn |